Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikoletta Nagy has a total of 474 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The importance of challenging dogma with patient data

    by Éva Ádám, Anita Hajdu, Kirsty Hodgson, Judit Danis, Nikoletta Nagy, Neil Rajan, Márta Széll

  • Open Access

    Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha

    by Kirsty Hodgson, Joseph Inns, Gary Reynolds, Emily Stephenson, Andrew Paul, Naomi Sinclair, Giacomo Berretta, Christopher Lawson, Andrew Michael Frey, Iglika Ivanova, et al.

    CYLD cutaneous syndrome (CCS) skin tumours develop from puberty onwards, can number in the hundreds and progressively grow over time. CCS patients lack medical therapies and require repeated surgery to control tumour burden. CYLD loss of heterozygosity (LOH) drives tumour growth, and CCS tumours have previously been shown to demonstrate increased canonical NF-κB and Wnt signalling. Here, we demonstrate evidence of non-canonical NF-κB signalling in CCS tumour keratinocytes, with increased p100 to p52 processing and RelB protein expression compared to normal skin. Utilizing complementary transcriptomics and proteomics on patient derived CCS tumour cell fractions, we identify IκB kinase alpha (IKKα) as a candidate target in the non-canonical NF-κB signalling pathway. A novel, highly selective, IKKα inhibitor (SU1644) used in patient derived CCS tumour spheroid cultures demonstrated that IKKα inhibition reduced tumour spheroid viability. These data provide the pre-clinical rationale for the assessment of topical IKKα inhibitors as a novel preventative treatment for CCS.


  • Open Access

    A Unique Patient Stratification Method Combined with a Machine Learning Approach Identifies Novel Genetic Susceptibility and Protective Factors for Severe COVID-19 in a Hungarian Population

    by Alexandra Neller, Mátyás Bukva, Bence Gálik, József Kun, Nikoletta Nagy, Ferenc Somogyvári, Valéria Endrész, Margit Pál, Barbara Anna Bokor, Zsófia Blazovich, et al.

    Intensive research has shown that severe COVID-19 outcomes are influenced by antiviral pathways and immune responses, both shaped by genetic predisposition. In this study, we aimed to identify genetic variants associated with disease severity in a cohort of Hungarian patients. We applied a novel stratification method based on age, disease severity, and clinical background to classify patients by susceptibility to severe COVID-19. Whole-exome sequencing (WES) was performed on 168 individuals, and gene mutation loads were assessed. Using a Random Forest machine learning approach, we identified variants of 877 genes that distinguished between severe and non-severe cases. We further categorized these genes as either susceptibility or protective factors. Gene-set enrichment analysis highlighted the most affected biological pathways. Our findings support the development of personalized diagnostic tools to assess the risk of severe COVID-19 and guide targeted treatment strategies. Our findings further extend the results of previous studies, providing novel insights into the genetic determinants of COVID-19 severity.

  • Open Access

    A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient

    by Barbara Anna Bokor, Aliasgari Abdolreza, Margit Pál, Zita Battyani, Márta Széll, Nikoletta Nagy

    Malignant melanoma is a complex malignancy with genetic, environmental, and lifestyle factors in its etiology. While germline variants in melanoma predisposition genes have been described, many patients remain genetically unexplained after panel testing. We previously analyzed a Hungarian melanoma cohort (n = 17), identifying variants in predisposing or susceptibility genes in 58.82% of patients. For individuals negative on this melanoma-specific panel, we expanded testing to a 19-gene panel associated with multiple cancer types. Next-generation sequencing was performed, followed by Sanger sequencing for confirmation. Variants were classified according to ACMG guidelines. In a 58-year-old female patient with a history of primary cutaneous melanoma, we identified a novel heterozygous frameshift variant in the tumor suppressor gene OBSCN (c.21322_21323insCTGG, p.G7108AfsTer10; NM_001386125.1). This insertion introduces a premature stop codon in exon 89 within the immunoglobulin-like domain, predicting protein truncation. Classified as likely pathogenic (PVS1, PM2), the variant is absent from population databases. To date, somatic OBSCN mutations have been reported in melanoma. This first report of a germline OBSCN frameshift variant in melanoma expands the genetic landscape of melanoma predisposition and suggests that OBSCN may represent a candidate gene contributing to melanoma risk.

  • Open Access

    Frequent cutaneous manifestations of rare monogenic dental diseases: a review of OMIM data and cases from own clinical practice

    by Nikoletta Nagy, Marta Szell

    In the last two decades, the elucidation of the genetic background of monogenic dental diseases has been significantly enhanced. In the Online Mendelian Inheritance in Man (OMIM) database there are 144 isolated or syndromic ones. Out of this 55 rare monogenic dental diseases (38%) are accompanied by cutaneous manifestations. In this study, we review the group of rare monogenic diseases with dental and cutaneous manifestations and observed the most frequent skin findings (hypohidrosis, hyperkeratosis, dry skin and skin fragility), nail symptoms (dysplastic nails and hypoplastic nails) and hair abnormalities (sparse hair, alopecia and hypertrichosis) and highlighted the genes associated with these frequent clinical features. We also summarized the frequent dental anomalies (missing teeth, abnormal shape of teeth, enamel abnormalities and delayed eruption or uneruption of teeth). Among the additional non-dental and non-cutaneous manifestations ophthalmological, skeletal and otorhinolaryngological abnormalities are the most frequently developing ones. Regarding the genetic background, there are 42 disease-causing genes associated with the 55 entities. Here, we also highlighted the WNT10A , CTSC and EDA1 associated diseases in order to demonstrate how different variants of these genes can lead to the development of different phenotypes. Reviewing rare monogenic dental-cutaneous diseases, the association of the identified special clinical features may raise the attention of the specialist in everyday clinical parctice and help in the identification of the underlying genetic background.

  • Oculocutaneous albinism type 1B associated with allelic combination of a risk haplotype

    by Nikoletta Nagy, Aliasgari Abdolreza, Margit Pál, Barbara Anna Bokor, Amarilla Barcsay-Veres, Noémi Ágnes Varga, Márta Medvecz, Viktória Szabó, Márta Széll


  • Open Access

    Novel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss

    by Nikoletta Nagy, Ágnes Szalenko-Tőkés, Margit Pál, Barbara Anna Bokor, Roland Nagy, János András Jarabin, László Róvó, Márta Széll

    Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL, and only four variants of the gene have so far been reported in this disease. Here, we report on a Hungarian ADNSHL family in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter but not carried by any unaffected family members. This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening, and therapeutic measures for each patient and hearing loss-prone families.


  • Open Access

    Truncating CYLD Pathogenic Variants in CYLD Cutaneous Syndrome Distinctly Influence CYLD Proteostasis and NF-κB Signaling

    by Éva Ádám, Balázs Leitgeb, Judit Danis, Anita Hajdu, Evelyn Kelemen, Margit Pál, Nóra Belső, István Balázs Németh, Neil Rajan, Nikoletta Nagy, et al.


  • Open Access

    Novel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss

    by Nikoletta Nagy, Ágnes Szalenko-Tőkés, Margit Pál, Barbara Anna Bokor, Roland Nagy, János András Jarabin, László Róvó, Márta Széll

    Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL and only four variants of the gene have so far been reported in this disease. (1) Here, we report on a Hungarian ADNSHL family, in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. (2) Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. (3) Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter, but not carried by any unaffected family members. (4) This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening and therapeutic measures for each patient and hearing loss-prone families.